Does Medicare Part D Cover Zepbound for Weight Loss? 2026 Criteria
If you’re a Medicare beneficiary hoping Part D will cover Zepbound for weight management, the news is largely discouraging. Below we detail the 2026 policy, why coverage is extremely restricted, and what alternatives exist.
Medicare’s Position on Zepbound
Simply put: Medicare Part D does not cover Zepbound for weight loss in 2026.
Zepbound (tirzepatide) was approved solely for chronic weight management — an anti-obesity medication. Long-standing Medicare policy prevents Part D coverage of drugs prescribed for weight loss.
The Wegovy comparison: Wegovy gained an additional FDA indication for cardiovascular risk reduction in patients with established ASCVD, which enabled a coverage pathway under a non-obesity classification. Currently, Zepbound/tirzepatide lacks a similar cardiovascular indication, leaving no Medicare coverage pathway.
Could this change?: Eli Lilly has ongoing cardiovascular outcome trials for tirzepatide (the SURPASS-CVOT program). Should the FDA grant cardiovascular risk reduction indication down the road, a Medicare Part D coverage pathway could open — mirroring the Wegovy CVD pathway.
What About Medicare Advantage?
Supplemental Medicare options follow the same Part D drug benefit rules. Not a single MA plan can cover Zepbound for weight loss within the prescription drug benefit.
Some Medicare Advantage plans have explored covering weight-loss services or programs under non-Part-D benefits, but prescription anti-obesity drugs don’t qualify under supplemental benefit rules in most cases.
Options If You’re on Medicare
When Medicare won’t cover Zepbound:
- Wegovy for CVD reduction: When the cardiovascular indication applies — this is the sole GLP-1 with a Medicare Part D coverage pathway
- Mounjaro for diabetes: When a concurrent diabetes diagnosis exists — Mounjaro (same molecule as Zepbound) has Part D coverage for T2D
- Ozempic for diabetes: Semaglutide for diabetes
- Rybelsus for diabetes: The tablet option
Medicare won’t cover Zepbound? Compounded semaglutide is available from licensed US telehealth providers for $199/month without insurance.
Frequently Asked Questions
Does Medicare Part D cover Zepbound for weight loss?
No. Medicare Part D does not cover Zepbound for weight loss. Anti-obesity medications are excluded from Part D.
Will Medicare ever cover Zepbound?
Possibly. If tirzepatide receives an FDA cardiovascular indication, a coverage opportunity could emerge — similar to the Wegovy CVD pathway.
Can I use Mounjaro instead of Zepbound on Medicare?
Yes, if you have type 2 diabetes. Mounjaro (same active ingredient as Zepbound) is covered by Part D for type 2 diabetes management. Off-label weight management is not covered.
Disclaimer: This article is for informational purposes only and does not constitute medical or insurance advice. Medicare coverage policies are complex and change annually. Consult your healthcare provider and your Medicare Part D plan for personalized guidance.